Dr. Timos Papagatsias’ Post

Thoughts on this? >> Young boy dies in trial for Pfizer Duchenne gene therapy - STAT >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharmaceutical #competitivemarketing #healthcare #biotech #pharma

Thoughts on this? >> Syncona Unveils Spur Therapeutics for Gene Therapy Advancements - TipRanks.com - TipRanks >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #competitivemarketing #biotech #pharma #pharmaceutical #healthcare

Thoughts on this? >> Pfizer's gene therapy for Duchenne muscular dystrophy fails trial - STAT >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharmaceutical #healthcare #pharma #biotech #competitivemarketing

Thoughts on this? >> FDA lifts hold on 4DMT's Fabry gene therapy >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #healthcare #pharma #biotech #pharmaceutical #productmarketing

Thoughts on this? >> FDA Approves First Gene Therapy To Treat Children With Metachromatic Leukodystrophy - Marketscreener.com >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #healthcare #biotech #pharmaceutical #pharma #competitivemarketing

Thoughts on this? >> Syncona Unveils Spur Therapeutics for Gene Therapy Advancements - TipRanks.com - TipRanks >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #healthcare #pharma #competitivemarketing #pharmaceutical #biotech

Thoughts on this? >> 4DMT's gene therapy reduced need for standard-of-care injections to treat age-associated vision loss >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharma #healthcare #biotech #pharmaceutical #productmarketing

Are you incorporating the impact of cell and gene therapies in your forecasts? Whether you are forecasting the uptake of a new cell and gene therapy or its impact on existing therapies, there are two major headwinds. First, one-off treatments such as cell and gene therapies eliminate their own treatable patient pool. Second, the uncertainty of a cell and gene therapy’s long-term effectiveness. Click to read about how to effectively overcome these forecasting challenges and reveal how existing chronic therapies may, in time, get a “second bite of the apple”. https://lnkd.in/ePg4TtAh Editor: Kim Robinson   #cellandgenetherapies #uptake #forecasting #pharma

Thoughts on this? >> FDA widens Sarepta’s Duchenne gene therapy label to older boys in significant expansion of use >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharmaceutical #healthcare #biotech #productmarketing #pharma

Thoughts on this? >> CRL delays first gene therapy for rare immune disorder - BioWorld Online >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #biotech #pharma #healthcare #competitivemarketing #pharmaceutical